CureVac Started the Day Worth More Than Novavax. Then Its Vaccine News Hit.

CureVac Started the Day Worth More Than Novavax. Then Its Vaccine News Hit.
·3 min read

Shares of vaccine start-up (CVAC) lost half their value in Wednesday’s after-hours trading following the German company’s announcement that the preliminary data from its Covid-19 study are disappointing. In a pivotal trial among 40,000 volunteers, the shots were 47% effective at preventing Covid symptoms. “While we were hoping for a stronger interim outcome, we recognize that demonstrating high efficacy in this unprecedented broad diversity of variants is challenging,” said CureVac chief executive Dr. Franz-Werner Haas.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting